CRX Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chaetocin | 28097-03-2 | sc-200893 | 200 µg | $120.00 | 5 | |
Chaetocin, a histone methyltransferase inhibitor, indirectly inhibits CRX by modulating chromatin structure. By inhibiting the histone methyltransferase activity, Chaetocin alters the epigenetic landscape associated with CRX, leading to changes in its expression and function. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, indirectly influences CRX activity by modulating chromatin acetylation. By inhibiting histone deacetylases, Trichostatin A promotes an open chromatin state that facilitates CRX expression and function. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1, a BET bromodomain inhibitor, indirectly inhibits CRX by disrupting the interaction between BET bromodomain proteins and acetylated chromatin. By preventing the binding of BET proteins to chromatin, JQ1 alters the epigenetic regulation of CRX, leading to changes in its expression and function. | ||||||
GSK-J4 Hydrochloride | 1797983-09-5 | sc-490344 | 5 mg | $260.00 | 1 | |
GSK-J4, a histone demethylase inhibitor, indirectly influences CRX activity by modulating chromatin methylation. By inhibiting histone demethylases, GSK-J4 alters the epigenetic landscape associated with CRX, leading to changes in its expression and function. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a DNA methyltransferase inhibitor, indirectly influences CRX activity by modulating DNA methylation. By inhibiting DNA methyltransferases, 5-Azacytidine alters the DNA methylation patterns associated with CRX, leading to changes in its expression and function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132, a proteasome inhibitor, indirectly inhibits CRX by preventing its degradation through the ubiquitin-proteasome system. By inhibiting the proteasome, MG-132 stabilizes CRX protein levels, leading to changes in its cellular abundance and function. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $36.00 $110.00 $400.00 | ||
BIX-01294, a G9a histone methyltransferase inhibitor, indirectly influences CRX activity by modulating histone methylation. By inhibiting G9a, BIX-01294 alters the epigenetic landscape associated with CRX, leading to changes in its expression and function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly influences CRX activity by modulating the PI3K signaling pathway. By inhibiting PI3K, Wortmannin alters downstream events that intersect with CRX-regulated pathways. The changed signaling induced by Wortmannin influences CRX-mediated cellular processes related to photoreceptor development and gene expression. | ||||||
(–)-Nutlin-3 | 675576-98-4 | sc-222086 sc-222086A | 1 mg 5 mg | $120.00 $215.00 | 2 | |
Nutlin-3, a small molecule inhibitor of MDM2, indirectly inhibits CRX by preventing its degradation through the ubiquitin-proteasome system. By disrupting the MDM2-CRX interaction, Nutlin-3 stabilizes CRX protein levels, leading to changes in its cellular abundance and function. The altered protein stability induced by Nutlin-3 influences CRX-mediated cellular processes related to transcriptional regulation and photoreceptor development. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $37.00 $77.00 $184.00 $510.00 $1224.00 $5814.00 | 8 | |
Niclosamide, an inhibitor of STAT3 signaling, indirectly influences CRX activity by modulating the JAK-STAT pathway. By inhibiting STAT3, Niclosamide disrupts downstream events that intersect with CRX-regulated pathways. The altered signaling induced by Niclosamide influences CRX-mediated cellular processes related to photoreceptor development and gene expression. | ||||||